SCHEDULE: Fuller & Thaler Asset Management Discloses Indivior Stake

Fuller & Thaler Asset Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 4,529,583.47 shares of Indivior Pharmaceuticals, Inc. common stock, representing 3.72% of the class.

Summary

• Fuller & Thaler Asset Management, Inc. has filed an amendment to its Schedule 13G, reporting its beneficial ownership of Indivior Pharmaceuticals, Inc. common stock.
• As of March 31, 2026, the firm beneficially owns 4,529,583.47 shares, which constitutes 3.72% of the total class of securities.
• The filing indicates sole voting power over 4,351,663.47 shares and sole dispositive power over 4,529,583.47 shares.
• This filing is made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, and the reporting person certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports existing ownership rather than new strategic developments or financial performance.

Positives

• Fuller & Thaler Asset Management, Inc. holds a significant minority stake (3.72%) in Indivior Pharmaceuticals, Inc., suggesting confidence in the company's value.
• The reporting person has sole voting and dispositive power over a substantial portion of their holdings, indicating clear control over their investment decisions.

Negatives

• The filing does not contain any negative financial information or operational concerns regarding Indivior Pharmaceuticals, Inc.

Risks

• The filing does not explicitly mention any risks associated with Indivior Pharmaceuticals, Inc. or the investment itself.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Indivior Pharmaceuticals, Inc.'s future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in public companies. Fuller & Thaler Asset Management's filing indicates a notable position in the pharmaceutical sector, specifically within Indivior Pharmaceuticals.

Stakeholder Impact

• Shareholders of Indivior Pharmaceuticals, Inc. are informed of a significant institutional investor's holdings, which can influence market perception and trading activity.

Next Steps

• Fuller & Thaler Asset Management will continue to monitor its investment in Indivior Pharmaceuticals, Inc.

Key Dates

Keywords

Indivior Pharmaceuticals, Fuller & Thaler Asset Management, Schedule 13G, Beneficial Ownership, SEC Filing, Common Stock, Investment Management, Securities Exchange Act